The use of rivaroxaban in deep venous thrombosis associated with vena cava inferior agenesis

Ali Ahmet Arıkan

doi:10.5606/tgkdc.dergisi.2019.17672

Ali Ahmet Arıkan¹, Selçuk Emre², Bayraktar Fatih Avni²

¹Department of Cardiovascular Surgery, Derince Training and Research Hospital, Kocaeli, Turkey
²Department of Cardiovascular Surgery, Muş State Hospital, Muş, Turkey

DOI : 10.5606/tgkdc.dergisi.2019.17672

Abstract
Turkish Abstract
Full Text
Full Text PDF
Similar Articles
E-mail to Author
How to Cite

Inferior vena cava agenesis is a rare anomaly which may result in deep vein thrombosis. There is no clear scientific evidence for the most effective therapeutic management, optimal duration, or the choice of anticoagulant therapy. Herein, we report an 18-year-old male case with deep vein thrombosis associated with inferior vena cava agenesis who was on rivaroxaban as a lifelong anticoagulation treatment for symptoms of venous stasis and the presence of heterozygotic thrombophilic mutations.

Keywords : Inferior, rivaroxaban, thrombophilia, vascular malformation, vein thrombosis, vena cava

Viewed : 4019

Downloaded : 1040